FL-APPLIED-DATA-CORP
5.10.2021 16:03:10 CEST | Business Wire | Press release
Applied Data Corporation (ADC), the global market leader for its SaaS-based total store operations platform built for retailers , today announced that it has entered into an agreement to acquire Pinpoint Software, Inc., a provider of software solutions driving operational efficiencies and execution for grocers and other retailers, including the world’s leading expiration date management platform, Date Check Pro® . The acquisition is a highly strategic addition to the ADC portfolio which includes ADC’s fresh item management platform, FreshIQ® , and fulfillment orchestration platform, ShopperKit, and will result in a solution that not only reduces food waste and delivers higher sales, but ultimately goes beyond sustainability to a more regenerative approach for retailers.
For most in the global retail space, food waste is a top concern that impacts the bottom line. As wasted food is the number one item going into landfills and contributing to GHG emissions, it is in everyone’s best interest to tackle this issue head-on. Both ADC and Pinpoint share a combined vision to arm retailers with the tools needed to drive sustainability results through a combination of quantification, analysis, and action.
“ADC’s trajectory as a total store operations platform continues to expand to meet the needs of retailers in today’s evolving market,” said Shamus Hines, CEO of ADC. “Pinpoint helps retailers proactively track inventory expiration dates across the store and work together with shoppers to minimize food waste.” Hines adds further, “As a company, we’re committed to enhancing all store operations for food retailers. With elevated consumer interest in sustainability, retailers are faced with the challenge to reduce food waste while also driving sales, and that is where both ADC and Pinpoint come into play.”
For nearly three decades, ADC has been a trusted provider to over 20,000 grocery and convenience store locations. The company’s SaaS platform of industry-tailored retail solutions already includes fulfillment orchestration, recipe management, made to order, label printing, inventory and waste management, food traceability, production planning, ordering, and temperature monitoring. With the addition of Pinpoint’s Date Check Pro , ADC will be able to offer additional reductions in shrink from expired products while also increasing customer satisfaction.
Andrew Hoeft, Founder and CEO of Pinpoint states, “At Pinpoint, we’ve always believed in driving efficiency and ensuring the freshest shopping experience possible for customers. ADC started in Fresh and has a strong belief in helping retailers reduce waste. Combined with our shared emphasis on user adoption with solutions that are easy to use and learn, joining forces with ADC was a perfect marriage. By blending our teams’ knowledge and solutions, we will continue to push the limits of retail operations technology.”
With this acquisition, work will immediately begin on an integration between the platforms in the coming weeks, the ADC website will be enhanced to show the full scope of the combined company.
About Applied Data Corporation
For more than 30 years, ADC has been a food technology innovator. Our platforms, FreshIQ® and ShopperKit, offer retailers an omnichannel approach to total store operations. FreshIQ allows retailers to effectively plan, prepare, analyze, and deliver the fresh food items shoppers want. The ShopperKit platform enables in-store order fulfillment for retailers to receive, prioritize, and process orders from their online counterparts allowing grocers to offer in-store pickup or delivery services to their online customers. ADC’s products are deployed globally in more than 120 grocery and convenience store chains and more than 20,000 locations. Visit www.applieddatacorp.com to learn more.
About Pinpoint
Pinpoint Software, Inc. is the parent company behind Date Check Pro. Founded in 2011 and based in the rapidly growing tech community and grocery tech hub of Madison, WI, Date Check Pro got its start when its founder Andrew Hoeft set out to solve the problem of expired shrink. Today, we help over a thousand supermarket, retail, and convenience store locations around the world eliminate their losses from dated and expired products and provide better products and experiences for their shoppers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005211/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
